Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
28 February 2019 | Story Ruan Bruwer | Photo Image SA
Wayde van Niekerk
Former UFS student Wayde van Niekerk, who still runs for the Kovsie Athletics Club, made his comeback after a long injury layoff.
Exactly 16 months and 16 days after seriously injuring his right knee, Wayde van Niekerk, the world and Olympic champion and record-holder in the 400 m, made a successful comeback to the track over the weekend.

His participation in the Free State Championship on Saturday (23 February 2019) was the former Kovsie sprinter’s first competitive race, which ended in a victory for the 26-year-old.

Van Niekerk won the 400 m in a time of 47,28 seconds. The former Marketing student still participates for the University of the Free State (UFS) Athletics Club.

According to his coach, Ans Botha, there is no immediate plans for a next race; this race only formed part of his training. They will be working towards the World Championships in September 2019, where he took gold in the 400 m at the previous two champs in 2017 and 2015. 

The international sprint sensation picked up medial and lateral tears of the meniscus, as well as a torn anterior cruciate ligament (ACL) while participating in a celebrity touch-rugby match back in October 2017.

He underwent surgery in the United States, followed by six months of rehabilitation in Doha under the watchful eye of Dr Louis Holtzhausen, well-known sports medicine physician. Holtzhausen was previously the head of the University of the Free State’s Department of Sports and Exercise Medicine.

In second place in the 400 m on Saturday was Cornel Fredericks, a hurdles specialist. Fredericks, gold medallist in the 400 m hurdles at the 2014 Commonwealth Games, is now also training under Botha.

News Archive

New research informs improved treatment of brain inflammation
2017-10-13

Description: Sebolai and Ogundeji Tags: Microbiologist, Dr Adepemi Ogundeji,  

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish



Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology. 

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs. 

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept